Martinez-Puente et al., 2024 - Google Patents

Analysis of the heterologous expression, localization, and cellular response to the Zika virus E protein in vitro

Martinez-Puente et al., 2024

View PDF
Document ID
7988299966853251384
Author
Martinez-Puente D
Lara-Lozano M
Aguirre-Pineda N
de Jesus Loera-Arias M
Ludert J
Segovia J
Publication year
Publication venue
Cellular and Molecular Biology

External Links

Snippet

Zika virus (ZIKV) infection has been associated with damage to neural stem cells in microcephaly in newborns. The virus possesses specific tropism for glioma stem cells mediated by the ZIKV E protein. This infection causes endoplasmic reticulum stress and …
Continue reading at www.cellmolbiol.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Holmes et al. A molecular understanding of alphavirus entry
Xie et al. Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID‐19 therapy
Tan et al. ZIKV infection activates the IRE1-XBP1 and ATF6 pathways of unfolded protein response in neural cells
Shah et al. Comparative flavivirus-host protein interaction mapping reveals mechanisms of dengue and Zika virus pathogenesis
Jalloh et al. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses
Cong et al. Enterovirus 71 2B induces cell apoptosis by directly inducing the conformational activation of the proapoptotic protein Bax
Ren et al. TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence
Kim et al. Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS‐CoV‐2 infection
JP2015509943A (en) TAM receptor as a viral entry cofactor
Benlarbi et al. Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron
Moschonas et al. MX2 forms nucleoporin-comprising cytoplasmic biomolecular condensates that lure viral capsids
Mao et al. TRIM21 promotes ubiquitination of SARS‐CoV‐2 nucleocapsid protein to regulate innate immunity
Xie et al. Japanese encephalitis virus NS2B-3 protein complex promotes cell apoptosis and viral particle release by down-regulating the expression of AXL
Mittler et al. LRP8 is a receptor for tick-borne encephalitis virus
Doyle et al. Endosomal fusion of pH-dependent enveloped viruses requires ion channel TRPM7
Yan et al. TMEΜ45B interacts with sindbis virus Nsp1 and Nsp4 and inhibits viral replication
Mazeaud et al. Zika virus remodels and hijacks IGF2BP2 ribonucleoprotein complex to promote viral replication organelle biogenesis
Yao et al. Interaction of chikungunya virus glycoproteins with macrophage factors controls virion production
Hayn et al. Imperfect innate immune antagonism renders SARS-CoV-2 vulnerable towards IFN-γ and-λ
Martinez-Puente et al. Analysis of the heterologous expression, localization, and cellular response to the Zika virus E protein in vitro
US20240398910A1 (en) Methods and compositions for the treatment of coronavirus infection, including sars-cov-2
Freppel et al. Flaviviruses alter endoplasmic reticulum-mitochondria contacts to regulate respiration and apoptosis
Essalmani et al. Implications of Spike-glycoprotein processing at S1/S2 by Furin, at S2’by Furin and/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2
Chazal et al. Chikungunya Virus Entry and Replication
Kang et al. Enhancement of MAVS UFMylation and inhibition of lysosomal degradation of MAVS aggregates: New findings on broad-spectrum antiviral mechanism of Anemoside B4